Subsidised access to TNFα inhibitors: Is the rationale for exclusion of rheumatoid-factor-negative patients defensible? (multiple letters) [1]

Medical Journal of Australia

Volumn 181, Issue 8, 2004, Pages 457-458

  Lu, Christine Y ^a   Williams, Kenneth M ^a   March, Lyn ^b   Bertouch, James V ^c   Day, Richard O ^a   Sansom, Lloyd N ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; HLA DR ANTIGEN; INFLIXIMAB; INTERLEUKIN 10; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

BONE EROSION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG RESPONSE; DRUG TARGETING; GENETIC POLYMORPHISM; HUMAN; LETTER; RHEUMATOID ARTHRITIS; SEROLOGY;

EID: 7044247960     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb06378.x     Document Type: Letter

References (0)